Patents by Inventor Alonso Ricardo
Alonso Ricardo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240156896Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.Type: ApplicationFiled: June 1, 2023Publication date: May 16, 2024Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
-
Patent number: 11965040Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: April 21, 2021Date of Patent: April 23, 2024Assignee: RA PHARMACEUTICALS, INC.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter, Robert Paul Hammer
-
Patent number: 11932705Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: August 29, 2022Date of Patent: March 19, 2024Assignees: MERCK SHARP & DOHME LLC, RA PHARMACEUTICALS, INC.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11814445Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: November 14, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Kelli Jette, Yili Sun
-
Patent number: 11814444Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: November 14, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Ketki Ashok Dhamnaskar, Zhong Ma, Jonathan C. Blain, Rohit Vyasamneni
-
Publication number: 20230303625Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: September 27, 2022Publication date: September 28, 2023Applicant: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole HA, Hyewon Youm, Mark W. EMBREY, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. GILBERT, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11752190Abstract: The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.Type: GrantFiled: October 8, 2020Date of Patent: September 12, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Steven James DeMarco, Michelle Denise Hoarty, Grace Victoria Parker, Alonso Ricardo, Sylvia Tobe, Douglas A. Treco
-
Patent number: 11723949Abstract: The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.Type: GrantFiled: August 12, 2021Date of Patent: August 15, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far
-
Patent number: 11707503Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: January 7, 2021Date of Patent: July 25, 2023Assignee: Ra Pharmaceuticals, Inc.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
-
Publication number: 20230122330Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: August 29, 2022Publication date: April 20, 2023Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
-
Publication number: 20230115176Abstract: The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.Type: ApplicationFiled: March 27, 2020Publication date: April 13, 2023Inventors: Willmen Wing-Menn Youngsaye, Bolin Geng, Michael R. Hale, Vincent P. Galullo, Jayashree G. Tikhe, Timothy Ryan Siegert, Alonso Ricardo, Derek M. LaPlaca, Douangsone D. Vadysirisack, Guo-Qing Tang, Kathleen Seyb, Michelle Denise Hoarty, Jonathan C. Blain, Joseph R. Stringer, Yongjin Gong, Claudio Sturino, Shawn Gallagher-Duval, Colin Diner, Burcin Akgun, Qing Cao, Douglas A. Treco, Vaishnavi Rajagopal, Ketki Ashok Dhamnaskar, Zhong Ma, Susan Ashwell, Jennifer Davoren, Xiaorong Liu, Camil Sayegh, Wenqing Xu, Alex Lemire, Audrey Belouin, Alexandria Jeanneret, Andrew Hildering, Barbara Bertani, Fabrizio MIcheli, Bemardo Pezzati, Alfonso Pozzan
-
Patent number: 11535650Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.Type: GrantFiled: April 19, 2022Date of Patent: December 27, 2022Assignee: RA PHARMACEUTICALS, INC.Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter, Robert Paul Hammer
-
Patent number: 11530244Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: December 20, 2022Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
-
Publication number: 20220370548Abstract: The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods for treating amyotrophic lateral sclerosis (ALS).Type: ApplicationFiled: September 11, 2020Publication date: November 24, 2022Inventors: Simon J. READ, Alonso RICARDO, Camil SAYEGH, Xiangyang XU, Yalan TANG, Guo-Qing TANG
-
Patent number: 11505575Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: November 22, 2022Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
-
Publication number: 20220348610Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: June 20, 2019Publication date: November 3, 2022Inventors: Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Ketki Ashok Dhamnaskar, Zhong Ma, Jonathan C. Blain, Rohit Vyasamneni
-
Publication number: 20220257697Abstract: The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods of treating neuromuscular inflammatory indications, such as Immune-Mediated Necrotizing Myopathy.Type: ApplicationFiled: June 4, 2020Publication date: August 18, 2022Inventors: Petra DUDA, Ramin FARZANEH-FAR, Alonso RICARDO, Camil SAYEGH, Nanqun ZHU, Douangsone D. VADYSIRISACK, Olivier BOYER, Laurent DROUOT
-
Publication number: 20220233632Abstract: The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.Type: ApplicationFiled: August 12, 2021Publication date: July 28, 2022Inventors: Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far
-
Publication number: 20220160820Abstract: The present disclosure provides compounds, compositions, and methods for modulating complement activity. Included are C5 inhibitor compounds and related methods of use in treating complement-related indications.Type: ApplicationFiled: March 6, 2020Publication date: May 26, 2022Inventors: Zhong Ma, Nanqun Zhu, Evan Thackaberry, Ramin Farzaneh-Far, Alonso Ricardo
-
Publication number: 20220133841Abstract: Embodiments of the present disclosure include methods of treating myasthenia gravis, including generalized myasthenia gravis, by providing C5 complement inhibitors. Included are devices and kits for inhibitor administration and methods of evaluating complement inhibitor treatment efficacy.Type: ApplicationFiled: October 22, 2019Publication date: May 5, 2022Inventors: Petra Duda, Ramin Farzaneh-Far, Zhong Ma, Nanqun Zhu, Evan Thackaberry, Alonso Ricardo